Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin plus AVD in pediatric advanced newly diagnosed Hodgkin lymphoma
jRCT2080223762Phase 2Completed
- Sponsor
- Takeda
- Start
- Dec 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by Takeda. Primary endpoints: Safety and tolerability of brentuximab vedotin plus AVD and Determination of recommended phase 2 dose of brentuximab vedotin. Started Dec 2017; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on jRCT2080223762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223762.